Skip to main content
OpenTrials
Completed

NCT Number: NCT05759936

4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing

Menopausal symptoms have a substantial effect on quality of life as well as potentially serving as markers for future health. Previous research has suggested that diet can impact menopausal symptoms. Seaweed is marketed as a treatment to alleviate menopause symptoms, but no research has tested whether it is effective in reducing the symptoms and psychological effects associated with menopause.

The aim of this study is to investigate the effects of consuming a seaweed supplement over a 4-week time period on menopausal symptoms and psychological well-being.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Online

Newcastle upon Tyne, NE1 8ST, United Kingdom

About this study

Menopause and peri-menopause are associated with a number of symptoms and psychological well-being. Previous literature has found a relationship between diet and menopause management. For example, following the Mediterranean diet consuming a variety of vegetables, fruits, legumes and whole grains has found to improve menopausal symptoms particularly vasomotor symptoms. Few studies have explored the effects of dietary supplements on psychological well-being in menopause. The aim of the study is to explore the impact of an iodine-rich seaweed food supplement on menopause symptoms and mental well-being in those experiencing menopause. Online assessments of symptoms will take place pre-intervention and post-intervention and will be compared to the effects of a placebo.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-assess as healthy
  • Experienced menopausal or peri-menopausal symptoms in the past 6 months

Exclusion criteria

  • Are currently taking HRT, anti-depressants, or anti-anxiety medication
  • Are lactating or pregnant (or seeking to become pregnant)
  • Have a thyroid disorder
  • Are currently taking iodine supplements
  • Have any relevant food intolerances

Treatment and study plan

500mg seaweed

Dietary Supplement

4 week supplementation of 1 capsule per day of seaweed

Placebo

Other

4 week placebo supplement of 1 capsule per day

Primary outcomes

  1. The Menopause-Specific Quality of Life Questionnaire (Hildtich, 1996)

    Time frame: At 28 days post-dose, adjusted for baseline

    The menopause-specific quality of life questionnaire assesses the effect of menopausal symptoms on quality of life in four domains: vasomotor, psychosocial, physical, and sexual; as well as providing a total score. The questionnaire has 29 items, each item is a symptom of menopause, the participants rate each symptom between 0 (not at all bothered) to 6 (bothered all the time.) The physical symptoms include items such as 'hot flushes' and 'sweating'; psychological symptoms include 'accomplishing less than I used to' and 'poor memory'; physical symptoms include 'difficulty sleeping' and 'weight gain'; sexual symptoms include 'vaginal dryness' and 'avoiding intimacy'. A conversion score is created for each of the 4 domains: vasomotor; psychosocial; physical; sexual; as well as a total score. Each score ranges from 1 -8, with higher scores indicating greater problems.

  2. Centre for Epidemiologic Studies Depression Scale (Radlof, 1997)

    Time frame: At 28 days post-dose, adjusted for baseline

    This is an established questionnaire used to measure symptoms associated with depression. The questionnaire has 20 items, including 'my sleep is restless', 'I felt depressed' and 'I felt lonely'. The participants rate the symptom on a scale between <1 day and 5 to 7 days, the 4 scale points are: Rarely or none of the time (less than 1 day); Some or a little of the time (1-2 days); Occasionally or a moderate amount of time (3-4 days); Most or all of the time (5-7 days). The possible range of scores is between 0 to 60, higher scores indicate more presence of symptomatology. The scoring of positive items is reversed.

  3. The State-Trait Anxiety Inventory (Spielberger, 1983)

    Time frame: At 28 days post-dose, adjusted for baseline

    The state-trait anxiety inventory will be used to measure anxiety levels, specifically trait anxiety. It consists of 20 items and the scale ranges from 1 to 4: 1 = almost never, 2 = sometimes, 3 = often and 4 = almost always. The nine positive items will be reversed for scoring, items 21, 23, 26, 27, 30, 33, 34, 36 and 39. The possible range of scores is 20 to 80, higher scores indicate higher levels of trait anxiety within the participant. Examples of items within the questionnaire include: 'I feel like a failure' and 'I feel secure'.

  4. The Perceived Stress Scale (Cohen et al., 1983)

    Time frame: At 28 days post-dose, adjusted for baseline

    This established questionnaire will be used to measure the perception of stress. Each of the ten items are rated on a scale between 0 (never) to 4 (very often.) The five scale points are 0 = never, 1 = almost never, 2 = sometimes, 3 = fairly often, 4 = very often. The four positive items will be reversed for scoring, items 4, 5, 7 and 8. The questionnaire item examples include 'In the last month, how often have you been upset because of something that happened unexpectedly?' and 'In the last month, how often have you felt that you were unable to control the important things in your life?'. The possible range of scores is between 0 to 40, higher scores indicate high participant perceived stress.

Sponsors and collaborators

Lead sponsor

Northumbria University

Other

Collaborators

  • Doctor Seaweed

Registry information

Official study title

Effects of 4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing - a Randomised, Placebo-controlled Trial

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Mar 8, 2023
Registry last updated
Mar 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.